Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
- “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
- “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
- Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
- Financial Results for the Three Months Ended December 31, 2023
Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.